← Back to Clinical Trials
Recruiting NCT06647017

NCT06647017 Delivering Transcutaneous Auricular Neurostimulation to Reduce Blood Loss During Dialysis AV Graft Placement Procedures

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06647017
Status Recruiting
Phase
Sponsor University Surgical Vascular
Condition Blood Loss, Surgical
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2024-11-13
Primary Completion 2026-11-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Volta tAN SystemSHAM Volta tAN System

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2024-11-13 with a primary completion date of 2026-11-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of this study is to determine if tAN therapy can reduce the volume of blood lost during dialysis AV graft placement procedures.

Eligibility Criteria

Inclusion Criteria: * Participant is undergoing a dialysis port placement procedure using synthetic graft * Participant is between 18 and 75 years of age * Participant is English proficient * Participant is able to provide informed consent and function at an intellectual level sufficient for study requirements Exclusion Criteria: * Participant has a BMI ≥ 40 * Participant is currently taking a platelet inhibitor medication * Participant has a history of epileptic seizures * Participant has a history of neurological diseases or traumatic brain injury * Participant has presence of devices, e.g., pacemakers, cochlear prosthesis, neurostimulators * Participant has abnormal ear anatomy or ear infection present * Person of childbearing age, not using adequate contraception as per investigator judgment or not willing to comply with contraception for the duration of the study * Person who is pregnant or lactating * Participant has any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial

Contact & Investigator

Central Contact

David Sailors, MD

✉ dsailors@gasurgery.com

📞 (706) 549-8306

Frequently Asked Questions

Who can join the NCT06647017 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Blood Loss, Surgical. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06647017 currently recruiting?

Yes, NCT06647017 is actively recruiting participants. Contact the research team at dsailors@gasurgery.com for enrollment information.

Where is the NCT06647017 trial being conducted?

This trial is being conducted at Watkinsville, United States.

Who is sponsoring the NCT06647017 clinical trial?

NCT06647017 is sponsored by University Surgical Vascular. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology